1. Medtech Insight
  2. >>Business

J&J To Pay $117M, Resolving Mesh Marketing Suits In 41 States

 
• By Elizabeth Orr

Johnson & Johnson and subsidiary Ethicon will pay $117m to settle state lawsuits alleging that their marketing misrepresented the safety and risks of transvaginal mesh devices.

Surgical knife and tension-free vaginal tape on pink background - Image

A multistate lawsuit alleging that Johnson & Johnson’s marketing for transvaginal mesh devices violated consumer protection laws is drawing to a close with the company’s agreement to pay $117m in settlements to 41 states and the District of Columbia.

The settlements, announced on 17 October, resolve claims that marketing for pelvic mesh products made by J&J and subsidiary Ethicon Inc. misrepresented the safety and effectiveness of the devices, and did not sufficiently disclose risks associated with their use

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

‘Pathologists Are Hungry For AI-Enabled Digital Pathology’

 
• By Natasha Barrow

Digital pathology makes it possible to unlock insights previously hidden to the human eye, “reshaping how we diagnose and treat patients,” said Nathan Buchbinder, co-founder and chief strategy officer at Proscia. He shared his views on the future of digital pathology and the lessons he has learned from working with pathologists.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 
• By Amanda Maxwell

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

UK Medtech Regulators Must Ensure Certainty So Businesses Can Plan Their Futures

 
• By Ashley Yeo

With medtech businesses typically managing investment cycles on a three- to five-year basis, local regulatory processes and forward costs of market entry must offer an attractive environment in which companies can plan for growth, says McDermott Will and Emery’s partner and head of healthcare and life sciences, Sharon Lamb. Broad-scale improvements to NICE’s evaluation offerings would similarly enhance the UK’s value to innovators.